Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro

Molecular Genetics and Metabolism

Volumn 88, Issue 2, 2006, Pages 114-122

  Bellezza, Ilaria ^a   Bracarda, Sergio ^a   Caserta, Claudia ^a   Minelli, Alba ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bicalutamide; EGFR; Gefitinib; Prostate cancer

Indexed keywords

AMPHIREGULIN; BETACELLULIN; BICALUTAMIDE; CISPLATIN; CYCLOPAMINE; FLUOROURACIL; GEFITINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NITROPRUSSIDE SODIUM; PHOSPHATIDYLINOSITOL KINASE; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB;

ANGIOGENESIS; APOPTOSIS; CELL PROLIFERATION; CORRELATION ANALYSIS; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ANDROGENS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33646415649     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2005.12.014     Document Type: Review

References (84)

1. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
2. Salomon D.S., Brandt R., Ciardello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19 (1995) 183-232
3. Sato B. Can an autocrine loop explain sex-hormone-dependent tumour growth? A brief overview. Oncology 57 Suppl 2 (1999) 3-6
4. Normanno N., Kim N., Wen D., Smith K., Harris A.L., Plowman G., Colletta G., Ciardiello F., and Salomon D.S. Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res. Treat. 35 (1995) 293-297
5. Prenzel N., Zwick E., Leserer M., and Ullrich A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2 (2000) 184-190
6. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., and Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284 (2003) 31-53
7. Engebraaten O., Bjerkvig R., Pedersen P.H., and Laerum O.D. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int. J. Cancer 53 (1993) 209-214
8. Shibata T., Kawano T., Nagayasu H., Okumura K., Arisue M., Hamada J., Takeichi N., and Hosokawa M. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol. 17 (1996) 168-175
9. Ravindranath N., Wion D., Brachet P., and Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J. Androl. 22 (2001) 432-443
10. Arteaga C.L. Epidermal growth factor receptor dependence in human tumours: more than just expression?. Oncologist 7 Suppl. 4 (2002) 31-39
11. De Miguel P., Royuela M., Bethencourt R., Ruiz A., Fraile B., and Paniagua R. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11 (1999) 722-727
12. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82 (1999) 241-250
13. Ennis B.W., Lippman M.E., and Dickson R.B. The EGF receptor system as a target for antitumour therapy. Cancer Invest. 9 (1991) 553-562
14. Ethier S.P. Signal transduction pathways: the molecular bases for targeted therapies. Semin. Radiat. Oncol. 12 (2002) 3-10
15. Fujino S., Enokibori T., Tezuka N., Asada Y., Inoue S., Kato H., and Mori A. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur. J. Cancer 32A (1996) 2070-2074
16. Pavelic K., Banjac Z., Pavelic J., and Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 13 (1993) 1133-1137
17. Harper M.E., Glynne-Jones E., Goddard L., Mathews P., and Nicholson R.I. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J. Pathol. 186 (1998) 169-177
18. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl 4 (2001) S9-S15
19. Magne N., Pivot X., Bensadoun R.J., Guardiola E., Poissonnet G., Dassonville O., Francoual M., Formento J.L., Demard F., Schneider M., and Milano G. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur. J. Cancer 37 (2001) 2169-2177
20. Tsutsui S., Kataoka A., Ohno S., Murakami S., Kinoshita J., and Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin. Cancer Res. 8 (2002) 3454-3460
21. Worthylake R., Opresko L.K., and Wiley H.S. ErbB-2 amplification inhibits downregulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem. 274 (1999) 8865-8874
22. Carpenter G. Employment of the epidermal growth factor receptor in growth factor-independent signalling pathways. J. Cell Biol. 146 (1999) 697-702
23. Festuccia C., Angelucci A., Gravina G.L., Biordi L., Millimaggi D., Muzi P., Vicentini C., and Bologna M. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumour cell dissemination. Thromb. Haemost. 93 (2005) 964-975
24. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., and Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumourigenicity. Proc. Natl. Acad. Sci. USA 91 (1994) 7727-7731
25. Pedersen M.W., Meltorn M., Damstrup L., and Poulsen H.S. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anticancer therapy. Ann. Oncol. 12 (2001) 745-760
26. Routh J.C., and Leibovich B.C. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin. Proc. 80 (2005) 899-907
27. Postma R., and Schroder F.H. Screening for prostate cancer. Eur. J. Cancer 41 (2005) 825-833
28. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Orthod. 20 (2002) 3001-3015
29. Ruijter E., van de Kaa C., Miller G., Ruiter D., Debruyne F., and Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev. 20 (1999) 22-45
30. Huggins C., and Hodges C.V. Studies on prostatic cancer: the effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1 (1941) 237-293
31. Labrie F. Endocrine therapy for prostate cancer. Endocrinol. Metab. Clin. North. Am. 20 (1991) 845-872
32. Rasmussen F. Treatment of advanced prostate cancer. Horm. Res. 32 Suppl. 1 (1989) 47-49
33. Sonnenschein C., Olea N., Pasanen M.E., and Soto A.M. Negative controls of cell proliferation. Human prostate cancer cells and androgens. Cancer Res. 49 (1989) 3474-3481
34. Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch A., Hittmair A., Bartsch G., Utermann G., Schneider M.R., Parczyk K., and Klocker H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 81 (1999) 242-251
35. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., and Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9 (1995) 401-406
36. Craft N., Chhor C., Tran C., Belldegrun A., DeKernion J., Witte O.N., Said J., Reiter R.E., and Sawyers C.L. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 59 (1999) 5030-5036
37. Culig Z. Role of the androgen receptor axis in prostate cancer. Urology 62 (2003) 21-26
38. Migliaccio A., Castoria G., Di Domenico M., de Falco A., Bilancio A., Lombardi M., Barone M.V., Ametrano D., Zannini M.S., Abbondanza C., and Auricchio F. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J. 19 (2000) 5406-5417
39. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., and Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
40. Kambhampati S., Ray G., Sengupta K., Reddy V.P., Banerjee S.K., and Van Veldhuizen P.J. Growth factors involved in prostate carcinogenesis. Front. Biosci. 10 (2005) 1355-1367
41. Culig Z., Steiner H., Bartsch G., and Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J. Cell Biochem. 95 (2005) 497-505
42. Craft N., Shostak Y., Carey M., and Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5 (1999) 280-285
43. Signoretti S., Montironi R., Manola J., Altimari A., Tam C., Bubley G., Balk S., Thomas G., Kaplan I., Hlatky L., Hahnfeldt P., Kantoff P., and Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92 (2000) 1918-1925
44. Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H., and Hung M.C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60 (2000) 6841-6845
45. Yeh S., Lin H.K., Kang H.Y., Thin T.H., Lin M.F., and Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 96 (1999) 5458-5463
46. Gioeli D., Mandell J.W., Petroni G.R., Frierson Jr. H.F., and Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59 (1999) 279-284
47. Pfeil K., Eder I.E., Putz T., Ramoner R., Culig Z., Ueberall F., Bartsch G., and Klocker H. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58 (2004) 259-268
48. Bonaccorsi L., Carloni V., Muratori M., Formigli L., Zecchi S., Forti G., and Baldi E. EGF receptor (EGFR) signalling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int. J. Cancer 112 (2004) 78-86
49. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., and Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54 (1994) 5474-5478
50. Nickerson T., Chang F., Lorimer D., Smeekens S.P., Sawyers C.L., and Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61 (2001) 6276-6280
51. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
52. Baserga R., Peruzzi F., and Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 107 (2003) 873-877
53. Culig Z., Comuzzi B., Steiner H., Bartsch G., and Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 92 (2004) 265-271
54. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
55. Rowinsky E.K. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 60 Suppl. 1 (2000) 1-14 discussion 41-42
56. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4 (2004) 361-370
57. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 Suppl. 4 (2002) 2-8
58. Goel S., Mani S., and Perez-Soler R. Tyrosine kinase inhibitors: a clinical perspective. Curr. Oncol. Rep. 4 (2002) 9-19
59. Raymond E., Faivre S., and Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl. 1 (2000) 15-23 discussion 41-42
60. Mendelsohn J., and Dinney C.P. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J. Urol. 165 (2001) 1152-1157
61. Herbst R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59 Suppl. 2 (2004) 21-26
62. Barton J., Blackledge G., and Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology 58 Suppl. 1 (2001) 114-122
63. Blackledge G., and Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br. J. Cancer 90 (2004) 566-572
64. Ciardiello F., and Tortor G. a A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7 (2001) 2958-2970
65. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
66. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., and Kris M.G. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 (2000) 4885-4892
67. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., De Placido S., Bianco A.R., and Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7 (2001) 1459-1465
68. Di Gennaro E., Barbarino M., Bruzzese F., De Lorenzo S., Caraglia M., Abbruzzese A., Avallone A., Comella P., Caponigro F., Pepe S., and Budillon A. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J. Cell Physiol. 195 (2003) 139-150
69. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., Bianco A.R., and Tortora G. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6 (2000) 2053-2063
70. Hammond L.A. Pharmacokinetic evaluation of gefitinib when administered with chemotherapy. Clin. Lung Cancer 5 Suppl. 1 (2003) S18-S21
71. Magne N., Fischel J.L., Tiffon C., Formento P., Dubreuil A., Renee N., Formento J.L., Francoual M., Ciccolini J., Etienne M.C., and Milano G. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br. J. Cancer 89 (2003) 585-592
72. Raben D., Helfrich B.A., Chan D., Johnson G., and Bunn Jr. P.A. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin. Oncol. 29 Suppl. 4 (2002) 37-46
73. Bianco C., Tortora G., Bianco R., Caputo R., Veneziani B.M., Caputo R., Damiano V., Troiani T., Fontanini G., Raben D., Pepe S., Bianco A.R., and Ciardiello F. Enhancement of antitumour activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8 (2002) 3250-3258
74. Vicentini C., Festuccia C., Gravina G.L., Angelucci A., Marronaro A., and Bologna M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J. Cancer Res. Clin. Oncol. 129 (2003) 165-174
75. Bonaccorsi L., Marchiani S., Muratori M., Forti G., and Baldi E. Gefitinib ('IRESSA,' ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J. Cancer Res. Clin. Oncol. 130 (2004) 604-614
76. Sgambato A., Camerini A., Faraglia B., Ardito R., Bianchino G., Spada D., Boninsegna A., Valentini V., and Cittadini A. Targeted inhibition of the epidermal growth factor receptor tyrosine kinase by ZD1839 (Iressa) induce cell cycle arrest and inhibits proliferation in prostate cancer cells. J. Cell Physiol. 201 (2004) 97-105
77. Alfano D., Franco P., Vocca I., Gambi N., Pisa V., Mancini A., Caputi M., Carriero M.V., Iaccarino I., and Stoppelli M.P. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb. Haemost. 93 (2005) 205-211
78. Formento P., Hannoun-Levi J.M., Gerard F., Mazeau C., Fischel J.L., Etienne-Grimaldi M.C., Gugenheim J., and Milano G. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur. J. Cancer 41 (2005) 1467-1473
79. Mimeault M., Moore E., Moniaux N., Henichart J.P., Depreux P., Lin M.F., and Batra S.K. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signalling inhibitors, in prostate cancer cells. Int. J. Cancer (2005) [Epub ahead of print]
80. Mimeault M., Jouy N., Depreux P., and Henichart J.P. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines. Prostate 62 (2005) 187-199
81. Sirotnak F.M., She Y., Lee F., Chen J., and Scher H.I. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent prostate cancer. Clin. Cancer Res. 8 (2002) 3870-3876
82. Torring N., Hansen F.D., Sorensen B.S., Orntoft T.F., and Nexo E. Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. Prostate 64 (2005) 1-8
83. Festuccia C., Gravina G.L., Angelucci A., Millimaggi D., Muzi P., Vicentini C., and Bologna M. Additive antitumour effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int. J. Cancer 115 (2005) 630-640
84. Boccon-Gibod L., Laudant M.H., Guiban D., and Steg A. Hormonal consequences of orchitectomy for carcinoma of the prostate. With special reference to the measurement of free testosterone in saliva and prostatic dihydrotestosterone levels. Eur. Urol. 15 (1988) 99-102